Food & Drug Administration (FDA) previously has cited that economic factors specifically, low profit margins for low-price prescription drugs as intermediaries (e.g., pharmacy benefit managers and wholesalers) have substantial market power to determine the price they will pay for generic drugs and that such savings are not always passed onto healthcare providers, patients or plan sponsors, per the hearing memo (PDF)
Pharmaceutical companies like Novo Nordisk and Eli Lilly want it both ways and continue to develop patent thickets made up of every minor modification of its products in order to extend patent protection that will increase the possibility of delaying competition and lengthening their market monopoly.As a result of this patent abuse, companies can maintain higher prices for longer, which then yields maximum revenue and profit to further enrich shareholders, all while perpetuating health inequities
The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa
Sucrose preference Procedure used to assess anhedonia or lack of response to pleasure in rodents that involves measuring the degree to which an animal preferentially selects a solution sweetened with sucrose over a non-sweet solution
Clinical trials lasted 48-68 weeks, with ongoing weight loss throughout
And vendor recommendations prioritize selling more product over achieving results
